Cardio Diagnostics Holdings (NASDAQ: CDIO) announced it will exhibit at four national benefits conferences in June to engage employers, brokers, union trustees and plan administrators on strategies to address cardiovascular disease, a leading driver of health plan costs and workforce productivity losses. The company will showcase its AI-powered cardiovascular risk assessment offerings, including Epi+Gen CHD(TM), PrecisionCHD(TM) and the HeartRisk(TM) population insights platform, designed to identify at-risk individuals earlier and help benefits decision-makers better manage healthcare costs and outcomes.
The announcement comes as cardiovascular disease remains the leading cause of death in the United States, accounting for nearly one in every four deaths. For employers and health plans, the financial burden is staggering: heart disease and stroke cost the U.S. health system an estimated $216 billion annually in direct medical costs and lost productivity, according to the Centers for Disease Control and Prevention. By identifying individuals at risk earlier, Cardio Diagnostics' solutions could enable earlier interventions, potentially reducing both clinical events and associated costs.
The company's offerings are built on a proprietary Artificial Intelligence-driven Integrated Genetic-Epigenetic Engine, which analyzes genetic and epigenetic markers to provide personalized risk assessments. The Epi+Gen CHD test evaluates coronary heart disease risk, while PrecisionCHD offers more detailed insights for targeted management. The HeartRisk platform aggregates population-level data to help plan sponsors identify high-risk groups and tailor wellness programs accordingly.
By engaging directly with benefits decision-makers at these conferences, Cardio Diagnostics aims to demonstrate how its technology can shift the focus from reactive treatment to proactive prevention. For employers, this could mean lower healthcare premiums, reduced absenteeism, and improved employee health outcomes. For union trustees and plan administrators, the tools offer a data-driven approach to managing the health of covered populations.
The company's participation underscores a broader trend in healthcare toward precision medicine and AI-driven analytics. As the cost of cardiovascular care continues to rise, stakeholders are increasingly seeking innovative solutions that deliver measurable returns on investment. Cardio Diagnostics' presence at these events may accelerate adoption of its technology among benefit plans seeking to control costs while improving member health.
For more details on the press release, visit https://ibn.fm/qFRHu. For the latest news and updates on Cardio Diagnostics, see the company’s newsroom at https://ibn.fm/CDIO.
